Icon (NASDAQ:ICLR) CFO Sells $307,510.08 in Stock

Icon Plc (NASDAQ:ICLR) CFO Bernard Clerkin sold 1,488 shares of the stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $206.66, for a total value of $307,510.08. Following the sale, the chief financial officer directly owned 7,171 shares in the company, valued at approximately $1,481,958.86. The trade was a 17.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Nigel Bernard John Clerkin also recently made the following trade(s):

• On Tuesday, August 11th, Bernard Clerkin sold 2,267 shares of Icon stock. The stock was sold at an average price of $164.29, for a total value of $372,445.43.

Icon Trading Down 0.7%

Icon stock opened at $201.65 on Friday. The stock has a 50-day moving average price of $174.57 and a 200 day moving average price of $146.92. Icon Plc has a 52 week low of $66.57 and a 52 week high of $219.04. The stock has a market cap of $15.44 billion, a PE ratio of 34.71, a P/E/G ratio of 11.25 and a beta of 1.19. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.37.

Icon (NASDAQ:ICLR) last released its earnings results on Tuesday, October 27th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.62 by $0.04. Icon had a net margin of 5.45% and a return on equity of 7.73%. The company had revenue of $2.02 billion for the quarter, compared to analyst estimates of $2.01 billion. During the same period in the prior year, the firm earned $3.31 EPS. The firm’s quarterly revenue was down .9% on a year-over-year basis. Equities research analysts predict that Icon Plc will post 9.71 earnings per share for the current fiscal year.

Institutional Trading of Icon

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC grew its stake in shares of Icon by 24.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 52,155 shares of the medical research company’s stock valued at $8,441,000 after buying an additional 10,389 shares during the period. Buckhead Capital Management LLC increased its holdings in shares of Icon by 0.9% during the 3rd quarter. Buckhead Capital Management LLC now owns 25,591 shares of the medical research company’s stock worth $4,350,000 after buying an additional 218 shares during the last quarter. Commonwealth Equity Services LLC raised its position in shares of Icon by 13.5% in the 3rd quarter. Commonwealth Equity Services LLC now owns 5,259 shares of the medical research company’s stock worth $894,000 after buying an additional 625 shares during the period. Bank Julius Baer & Co. Ltd Zurich raised its position in shares of Icon by 0.4% in the 3rd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 20,762 shares of the medical research company’s stock worth $3,529,000 after buying an additional 79 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Icon in the 3rd quarter worth $38,000. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Analyst Upgrades and Downgrades

ICLR has been the topic of several recent analyst reports. Bank of America raised shares of Icon from an “underperform” rating to a “neutral” rating and set a $185.00 price objective on the stock in a research note on Friday, October 9th. Barclays lifted their target price on shares of Icon from $175.00 to $230.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 29th. William Blair raised shares of Icon to a “strong-buy” rating in a research note on Thursday, July 30th. TD Cowen boosted their price target on Icon from $197.00 to $254.00 and gave the company a “buy” rating in a report on Thursday, October 29th. Finally, Weiss Ratings raised Icon from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Icon presently has a consensus rating of “Moderate Buy” and a consensus target price of $213.76.

Icon Company Profile

ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.